AVTR - Avantor to boost production capacity to meet the growing demand for biologics and vaccines

Avantor ([[AVTR]] +0.5%) announced plans to expand its global capacity in single-use technologies used for the production of biologics and vaccines.In a statement, the company highlighted its efforts to increase the single-use manufacturing footprint by 30% and double the cleanroom space.The plans are aimed at meeting the rising ‘demand for monoclonal antibodies (mAbs), novel cell and gene therapies for oncology and other diseases, as well as vaccines, including those for COVID-19’ Avantor said."The industry's response to the COVID-19 pandemic has relied heavily on the integration of single-use products into biopharma production processes,” noted Dr. Ger Brophy, the executive vice president of Biopharma Production at Avantor."These additions to our global single-use manufacturing ecosystem are critical steps in enabling our customers to get therapies to patients quickly," Brophy continued.Avantor recently expanded its Morrisville, North Carolina, single-use facility. By mid-2021, it expects to commission a second European single-use facility in Hillegom, the Netherlands, and

For further details see:

Avantor to boost production capacity to meet the growing demand for biologics and vaccines